Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance

Momin, Aziz; Melikian, Narbeh; Shah, Ajay M.; Grieve, David; Wheatcroft, Stephen; John, Lindsay C.H.; Gamel, Adam El; Desai, Jatin; Nelson, Toby L.; Driver, Catherine; Sherwood, Roy; Kearney, Mark T.

doi:10.1093/eurheartj/ehi831

Cited by 91 publications

(83 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Somewhat conversely, leptin appears to be a potent vasodilator in those with coronary artery disease (Momin et al 2006). Moreover, in rodents, leptin has been demonstrated to phosphorylate eNOS leading to NO release (Rodriguez et al 2007).…”

Section: Leptinmentioning

confidence: 98%

Role of adipokines in cardiovascular disease

Mattu¹,

Randeva²

2012

Journal of Endocrinology

251

203

View full text Add to dashboard Cite

The discovery of leptin in 1994 sparked dramatic new interest in the study of white adipose tissue. It is now recognised to be a metabolically active endocrine organ, producing important chemical messengers -adipokines and cytokines (adipocytokines). The search for new adipocytokines or adipokines gained added fervour with the prospect of the reconciliation between cardiovascular diseases (CVDs), obesity and metabolic syndrome. The role these new chemical messengers play in inflammation, satiety, metabolism and cardiac function has paved the way for new research and theories examining the effects they have on (in this case) CVD. Adipokines are involved in a 'good-bad', yin-yang homoeostatic balance whereby there are substantial benefits: cardioprotection, promoting endothelial function, angiogenesis and reducing hypertension, atherosclerosis and inflammation. The flip side may show contrasting, detrimental effects in aggravating these cardiac parameters.

show abstract

Section: Leptinmentioning

confidence: 98%

Role of adipokines in cardiovascular disease

Mattu¹,

Randeva²

2012

Journal of Endocrinology

251

203

View full text Add to dashboard Cite

show abstract

“…Furthermore, some cardio protective effects of leptin have been reported in experimental settings. 22,23 In CKD, the clinical significance and prognostic implications of leptin and adiponectin are not well understood. Patients with CKD have increased circulating levels of both adipokines that may result from an increase in their systemic production and/or decrease in their renal clearance.…”

Section: Introductionmentioning

confidence: 99%

Adiponectin, leptin, nitric oxide, and C-reactive protein levels in kidney transplant recipients: comparison with the hemodialysis and chronic renal failure

2016

View full text Add to dashboard Cite

Background: Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with chronic kidney disease (CKD) including kidney transplant recipients (KTR). Secondary lipid metabolism disorders, endothelial dysfunction, and inflammation enhance the risk of CVD development in these patients. The aim of the present study was to investigate the lipid profile, adiponectin, leptin, nitric oxide (NO), and high sensitivity C-reactive protein (hs-CRP) levels in KTR and to compare these parameters with those of the patients with chronic renal failure (CRF), hemodialysis (HD) patients, and healthy controls. Methods: Serum adiponectin and leptin levels were measured by radioimmunoassay; hs-CRP was determined immunoturbidimetrically. Determination of NO was based on the Griess reaction. Results: Compared with the control group, serum NO and adiponectin levels were significantly higher in the KTR, CRF, and HD groups; hs-CRP levels were significantly higher in the KTR and HD groups; leptin levels were significantly higher in the KTR. In addition, serum NO level was significantly higher in the KTR compared to CRF cases. Adiponectin correlated positively with high density lipoprotein-cholesterol in the control and patient groups. A positive correlation was observed between hs-CRP and NO in the KTR and the patients with CRF. Serum adiponectin levels were inversely correlated with hs-CRP and leptin in the HD group. Conclusion: KTR suffer from inflammation and accompanying changes in levels of adipocytokines and NO which contribute to the increased risk of CVD in these patients.

show abstract

“…Elevated serum leptin concentrations in humans are associated with myocardial infarction and stroke independently of traditional cardiovascular risk factors and obesity status (18), as well as with insulin resistance, inflammation, disturbances in hemostasis (19), hypertension (20), and the extent of coronary artery calcification in women (21). On the other hand, leptin has been proven to be an efficient vasodilator in humans with coronary artery disease (22). It has been proposed that leptin could play a role in the pathogenesis of atheromatous plaques acting synergistically with other inflammatory mediators (23).…”

Section: Leptinmentioning

confidence: 99%

Cardiometabolic comorbidities and rheumatic diseases: Focus on the role of fat mass and adipokines

Lago¹,

Gómez²,

Conde³

et al. 2011

Arthritis Care & Research

View full text Add to dashboard Cite

Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance

Abstract: Leptin is a vasoactive peptide in human SV and internal mammary artery. Its action is not nitric oxide or endothelial-dependent. Markers of body fat did not correlate with leptin-mediated vasodilatation, raising the intriguing possibility of selective resistance to leptin's actions.

Cited by 91 publications

References 39 publications

Role of adipokines in cardiovascular disease

Role of adipokines in cardiovascular disease

Adiponectin, leptin, nitric oxide, and C-reactive protein levels in kidney transplant recipients: comparison with the hemodialysis and chronic renal failure

Cardiometabolic comorbidities and rheumatic diseases: Focus on the role of fat mass and adipokines

Contact Info

Product

Resources

About